FdaApplication
NDA 210868
Identifiers
- fda_app_no: NDA210868
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2018-11-02 |
Revenue by product
LORBRENA
| Period | Revenue |
|---|---|
| Q2 2026 | $354.0M |
| Q1 2026 | $305.0M |
| Q3 2025 | $268.0M |
| Q2 2025 | $251.0M |
| Q1 2025 | $222.0M |
| Q3 2024 | $206.0M |
| Q2 2024 | $169.0M |
| Q1 2024 | $164.0M |
| Q4 2023 | $146.0M |
| Q3 2023 | $159.0M |
| Q2 2023 | $121.0M |
| Q1 2023 | $112.0M |
| Q4 2022 | $96.0M |
| Q3 2022 | $99.0M |
| Q2 2022 | $77.0M |
| Q1 2022 | $72.0M |
| Q4 2021 | $73.0M |
| Q3 2021 | $67.0M |
| Q2 2021 | $66.0M |
| Q1 2021 | $60.0M |
| Q4 2020 | $62.0M |
| Q3 2020 | $55.0M |
| Q2 2020 | $46.0M |
| Q1 2020 | $42.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| LORBRENA | LORLATINIB | 25MG | TABLET;ORAL |
| LORBRENA | LORLATINIB | 100MG | TABLET;ORAL |
2 products